Current Management of Amaurosis Fugax

The Amaurosis Fugax Study Group

We present a consensus on the pathophysiology, etiology, diagnosis, and treatment of amaurosis fugax. The phenomenon is defined and described, and the roles that extracranial and ocular vascular diseases play are discussed. Nonvascular ophthalmic and neurologic disorders that can be confused with amaurosis fugax are listed, and an algorithm for evaluation (which includes ophthalmic examination, laboratory studies, and noninvasive carotid artery studies) is given. Treatment of atherosclerosis, carotid artery disease, and other causes of amaurosis fugax are also discussed. (Stroke 1990;21:201–208)

Heightened interest in amaurosis fugax stimulated the organization of a symposium and the preparation of a review on this subject emphasizing newer information regarding pathogenesis, diagnosis, and treatment. This article summarizes the collective current views of the authors, who represent the specialties of neurology, neuroophthalmology, ophthalmology, neurosurgery, hematology, and vascular surgery. The method of preparation of this article closely followed the practices used at National Institutes of Health consensus development conferences and is based on the belief that consensus formulation is a useful approach to controversial issues when the available data are inadequate to resolve difficult questions.

This document reflects the opinions of the Amaurosis Fugax Study Group, the members of which were selected to represent a balance and breadth of expertise. While individual differences of opinion may exist regarding some of the statements in this report, the Group was able to achieve a consensus on all of the issues examined. We believe that these views are based on the available scientific data and that they may be useful to the practicing physician.

Pathophysiology—Definition and Description of the Phenomenon

Amaurosis fugax is defined as transient monocular visual loss attributed to ischemia or vascular insufficiency. Typically, patients describe diminished or absent vision in one eye that progresses over a few seconds and lasts for seconds to a few minutes. The impairment progressively may involve the entire visual field. The loss of vision usually begins in the upper field, less frequently in the periphery, and rarely in the lower field. Patchy and sectorial loss...
TABLE 1. Causes of Transient Monocular Blindness

**Embolic**
- Carotid bifurcation thromboembolism
- Great vessel or distal internal carotid artery atheroembolism
- Cardiac emboli (valve, mural thrombi, intracardiac tumor)
- Drug abuse-related intravascular emboli

**Hemodynamic**
- Extensive atheromatous occlusive disease
- Inflammatory arteritis (Takayasu’s disease)
- Hypoperfusion (cardiac failure; acute hypovolemia; systemic diseases disturbing blood viscosity, coagulability, or content)

**Ocular**
- Anterior ischemic optic neuropathy
- Central or branch retinal artery occlusion (often embolic)
- Central retinal vein occlusion
- Nonvascular causes (hemorrhage, pressure, tumor, congenital)

**Neurologic**
- Brainstem, vestibular, and oculomotor
- Optic neuritis, optic nerve or chiasm compression
- Papilledema
- Multiple sclerosis
- Migraine
- Psychogenic

**Idiopathic**

May also occur. Recurrent events tend to follow the same pattern.

The majority of attacks occur without obvious precipitating factors. Uncommonly, the visual loss lasts for several hours and yet full recovery occurs. Persistent visual loss after such an event is an indication of retinal or optic nerve infarction.

**Etiology**

**Extracranial Cerebrovascular Disease**

**Thromboembolic.** The visual disturbance in amaurosis fugax is a sudden episode of partial or complete monocular visual loss that lasts seconds to minutes, followed by complete recovery. Some of the attacks are considered to be due to embolism into the ophthalmic circulation from the ipsilateral common carotid artery and its branches, particularly in patients >50 years of age (Table 1). Amaurosis fugax may be an important marker of generalized atherosclerotic disease. The carotid atherosclerotic lesion may be an occlusion, a stenosis, or an irregular ulcerated lesion with or without stenosis.\(^{3-7}\) Stenosis of >75% may be associated with thrombus formation in the poststenotic cul-de-sac. Other carotid pathology responsible for the episode may include fibromuscular dysplasia, spontaneous dissection, and aneurysm of the carotid bifurcation. Material seen within the retinal arteries indicates embolism, and emboli may be seen even after vision has returned to normal. Bright, yellowish, glinting lipid emboli, so-called Hollenhorst plaques, are the most common emboli seen in the eye.\(^{8-10}\) The emboli most often are associated with atheromatous lesions of the ipsilateral carotid artery or, less frequently, with atherosclerotic disease involving the aortic arch or the carotid siphon and contain cholesterol.\(^{11}\) Isolated cholesterol crystals are observed occasionally. Pale or migrant emboli are composed of fibrin and platelets.\(^{12}\) Calcific emboli, which are characteristically white and non-scintillating, may originate from the common carotid artery, more proximal arterial sites, or from calcific cardiac valvular disease.\(^{13,14}\) Amaurosis fugax associated with atherosclerotic occlusive disease may precede occlusion of the central retinal artery, occlusion of a branch retinal artery, or anterior ischemic optic neuropathy. Emboli of cardiac origin may reach the eye from valvular disease, such as rheumatic heart disease, mitral valve prolapse, marantic or infectious endocarditis, or calcific valvular disease. Patients with intracardiac lesions such as myxomas or mural thrombi (e.g., lesions associated with atrial fibrillation or myocardial infarction) usually have larger emboli that do not reach the eye. Retinal emboli from intravenous drug abuse may produce transient monocular visual loss, and talc or other foreign intravascular material may be seen on opthalmoscopy.\(^{15,16}\)

**Hemodynamic.** Less frequently, amaurosis fugax may occur in patients with extensive atherosclerotic extracranial arterial occlusive disease, particularly involving several of the aortic arch branches. Visual loss under these circumstances is precipitated by a change in posture, by exercise, or by exposure to bright light and is due to retinal vascular insufficiency.\(^{17,18}\) The temporary hemodynamic episodes of monocular visual loss may be less rapid in onset than the brief transient attacks of embolic origin, with the visual loss developing over minutes rather than seconds and lasting slightly longer than embolic episodes. Recovery may take place more gradually. Symptoms of cerebral ischemia may coexist. The pattern of attacks in association with physical activity suggests a temporary inadequacy of the retinal circulation and retinal or choroidal ischemia. Compensation becomes inadequate when both the external carotid artery and the internal carotid artery (ICA) are severely stenotic or occluded. In young women, the cause may be inflammatory arteritis (Takayasu’s disease). Hypoperfusion due to low cardiac output or acute hypovolemia may cause amaurosis fugax that is usually bilateral. If unilateral, it is commonly associated with preexisting asymmetric occlusive vascular disease. Systemic diseases can alter ocular blood flow and produce transient monocular visual loss by disturbing blood viscosity, cellular blood content, or blood coagulability. Rarely, patients have retinal migraine with transient visual loss thought to be due to vasospasm in the retinal arterial system.\(^{19-21}\)

**Idiopathic.** Some patients with monocular blindness have no demonstrable ocular or systemic explanation for their symptoms. At present, the cause in these patients must be considered idiopathic. In some of these patients the mechanism may be vasospastic.
Ocular Vascular Diseases

Anterior ischemic optic neuropathy due to giant-cell arteritis, atherosclerosis, or thrombosis in situ affects persons ≥60 years of age and may produce amaurosis fugax. The visual loss is caused by severe narrowing or occlusion of the posterior ciliary arteries, with consequent acute ischemia of the optic nerve head. Fatigue, malaise, headache, and polymyalgia rheumatica often precede or accompany the visual symptoms.

Occlusion of the central retinal vein sometimes begins with attacks of amaurosis fugax due to transient slowing of the retinal arterial circulation produced by sudden occlusion of the central retinal vein. The funduscopic findings in this condition are characteristic and include engorged retinal veins and multiple retinal hemorrhages.

Malignant arterial hypertension in some patients causes amaurosis fugax due to ischemia of the optic nerve head. This is always accompanied by optic disk edema in addition to other ophthalmoscopic signs of hypertension. Headache, seizures, encephalopathy, and decreased renal function are also usually present.

Conditions That Can Be Confused With Amaurosis Fugax

Nonvascular ophthalmic disorders may present with transient monocular visual loss. Among these conditions are transient changes in the ocular media or intraocular pressure, such as vitreous floaters, vitreous hemorrhage, anterior chamber hemorrhage, and glaucoma. Congenital anomalies of the optic disk, such as drusen or posterior staphyloma, also should be considered. Intraorbital masses may produce gaze-evoked amaurosis fugax.

Neurologic disorders also can cause temporary visual loss that patients localize to one eye or do not localize precisely. Brainstem, vestibular, and oculo-motor lesions cause blurred vision, usually with rotation, oscillation of objects, or diplopia. Intraorbital tumors, optic neuritis, and compression of the optic nerve or optic chiasm by aneurysms or tumors usually cause more gradual and persistent monocular visual loss. Patients with papilledema from any cause may note transient visual obscurations.

Neurologic disorders, such as migraine, that affect postchiasmal visual pathways cause homonymous defects in the visual field that the patient may describe erroneously as monocular. Sequential eye closure tests for visual acuity and examination of the visual fields help localize the lesion. Scintillations, hallucinations, and the presence of other neurologic findings also identify a cerebral location. Visual loss also can be psychogenic.

Diagnostic Evaluation

Pace of the Evaluation

Because of the brief interval between the transient event and a stroke or blindness from temporal arteritis, the workup for transient monocular blindness should be undertaken without delay. In the absence of temporal arteritis, the outlook for vision is good, but the risk of stroke approaches that for hemispheric transient ischemic attack (TIA). Simultaneous evaluation of occult cardiac disease is justified by the high frequency of cardiac mortality among patients with this symptom. An algorithm for the evaluation of transient monocular blindness is presented in Figure 1. The patient's history should help differentiate embolic amaurosis fugax from atypical visual spells due to a variety of other nonischemic mechanisms.
Ophthalmic Examination

A complete examination by an ophthalmologist or a neuro-opthalmologist should seek evidence of unusual causes as well as those that support a diagnosis of embolic and retinal vascular disease.39 Ocular signs of ischemia include occlusion of a branch retinal artery, regional retinal pallor, microinfarcts, and small hemorrhage(s).34,10,40,41 Distended, irregular veins and peripheral microanenuysms suggest retinal vascular insufficiency. These retinal vascular changes are best visualized by fluorescein angiography. Unusual detectable causes include narrow-angle glaucoma, intraocular hemorrhage, congenital anomaly of the optic disk, disk drusen, and orbital tumor.

Laboratory Studies

A few laboratory tests are recommended to detect associated systemic illnesses: a complete blood count for evidence of polycythemia or leukemia, a platelet count for evidence of thrombocytosis, a Westergren sedimentation rate for evidence of giant-cell arteritis, and screening for hyperlipidemia and diabetes mellitus.42–44 The value of a routine search for a prethrombotic state, with tests for the lupus anticoagulant and deficiencies in protein C, protein S, or antithrombin III, has not been established, but such tests are warranted in younger patients or those with systemic symptoms, known malignancy, or other systemic diseases.45

Noninvasive Carotid Artery Studies

High-quality duplex ultrasound studies of the carotid artery are recommended strongly to identify occlusion, stenosis, or major ulceration at the carotid bifurcation and lesions of the proximal great vessels. If the results are positive, these studies are an indication for arch and carotid angiography.6,46–48 If the results of carotid duplex examination are normal or show only minor irregularities, evidence of intracranial stenosis at the level of the carotid siphon should be sought by pneumoplethysmography, ophthalmodynamometry or, particularly, transcranial Doppler examinations. Computed tomography or magnetic resonance imaging is recommended and may provide evidence of clinically silent cerebral embolism.49–52

If results of the duplex and intracranial tests show no abnormalities, renewed diagnostic efforts may be made. Under these circumstances, a fluorescein angiogram is advisable to document previous embolic occlusion, microinfarction, ischemia in the posterior ciliary arteries territory, or poor retinal perfusion since carotid angiography is usually inadequate to document ophthalmic artery disease.53,54

When the results of a high-quality duplex study are normal, the morbidity associated with angiography must be balanced against the low yield of further information provided by angiography and the low risk of stroke in patients with normal duplex studies.55–57 Accordingly, routine carotid angiography is not recommended when the results of ultrasound examination are normal. Intravenous digital subtraction angiography is no longer indicated because of its low resolution.58 Other imaging approaches, such as thrombus-directed imaging procedures with low density lipoproteins or labeled platelet studies and Doppler-documented plaque morphology to determine the activity of the carotid sinus mural thrombus, are not yet of established value.48,59 Ultrasonic documentation of plaque morphology is promising, but its role has not been defined yet.

When associated with carotid artery disease, amaurosis fugax is a marker of increased risk of death from myocardial infarction.37 Therefore, patients in whom carotid atherosclerosis is demonstrated should have a cardiac assessment, both to identify cardiac sources of emboli and to detect those patients with ischemic heart disease.50,60,61

At the end of the investigation, approximately 11% of patients <50 years of age will be found to have no cause for their visual loss and no history of migraine.62 Invasive procedures are not warranted in these patients, but careful follow-up is mandatory.63

Treatment

Some ocular vascular diseases and conditions associated with amaurosis fugax have specific treatments. Especially important is the recognition and treatment of giant-cell arteritis and glaucoma. In addition, therapy is largely noncontroversial for the majority of other ocular vascular causes and the conditions that can be confused with amaurosis fugax. Emphasis here is directed to those conditions associated with occlusive vascular disease resulting in amaurosis fugax for which treatment is controversial or unproven.

Atherosclerosis

General comments. The efficacy of all forms of present therapy is uncertain because of insufficient data. Most reports of therapy lump together amaurosis fugax and cerebral hemispheric TIA, but the natural history of these two conditions may be different. The accepted primary implication is that amaurosis fugax caused by a carotid embolism is a precursor of hemispheric stroke.64,65 In a recent British study, the annual incidence rate of stroke in patients with this disorder was 2%,34 four times that expected in a matched population sample, but the expected annual stroke rate after a hemispheric TIA is substantially greater.66,67 Blindness must also be considered a sequela of amaurosis fugax that may be prevented by treatment.

Carotid endarterectomy has been shown to be safe and effective in preventing stroke and blindness after amaurosis fugax in two recent reports.68,69 The combined mortality and permanent neurologic deficit rate in the experience of the University of California, San Diego, was 1.9%; at the Scripps Clinic it was 1.3%;68 and at the University of California, San Francisco, it was 3%.69 Life table analysis of these patients following successful endarterectomy indi-
Suggested treatment plan for patients with transient monocular blindness.

Carotid Artery Disease

The identification of plaque ulceration in patients with any of the categories of carotid stenosis may lead some physicians to a more aggressive approach in therapy because emboli of platelet-fibrin thrombi, atheromatous debris, and cholesterol crystals may be released from these ulcerated areas. Plaque appearance and composition (i.e., degree of ulceration, hemorrhage, calcification, and lipid deposition) may have important clinical implications and may affect thinking about appropriate therapy. The specific recommendations that follow are based on the degree of ICA stenosis or occlusion (Figure 2).

Occlusion. Transient attacks, either ocular or cerebral, are less common in patients with ICA occlusion than in those with ICA stenosis. Furthermore, amaurosis fugax may cease when a stenotic artery becomes occluded. Therefore, when a patient with amaurosis fugax is found to have a complete ICA occlusion, it is reasonable to treat the risk factors for carotid artery disease, give aspirin, and await developments. If amaurosis fugax continues, the cause may be embolism due to thrombus propagated from the carotid siphon or the occluded ICA stump traveling through external carotid collaterals. The cause also may be ischemia in a marginally perfused hemisphere or eye. Certain specific lesions associated with ICA occlusion and capable of producing amaurosis fugax can be corrected by surgery (e.g., external carotid artery ulceration or stenosis and ICA stump thrombosis with embolism).

Stenosis of >75% (surgically inaccessible site). In some patients, especially those with severe hypertension or diabetes mellitus, carotid atheroma may be diffuse or localized at an inaccessible site (usually in the carotid artery siphon) with or without accompanying disease at the carotid bifurcation. In this group, aspirin therapy combined with general measures against the underlying disease and risk factors are recommended. Some clinicians prefer anticoagulation if hypertension can be controlled.

cates that at least 95% will be free of ipsilateral stroke for 8 years in all three series. However, results will vary from surgeon to surgeon. Thus, the decision for surgical referral must be weighed against the morbidity and mortality rates of the individual surgeon involved, as well as against the natural history of the condition.

Aspirin reduces the prevalence of stroke plus death and of further TIA in patients with TIA. Although the reduction in stroke alone has not been significant in most single studies, pooled data strongly suggest some benefit. Patients with amaurosis fugax have constituted approximately 15% of the subjects of these trials, and it is assumed that the results of the trials apply to patients with amaurosis fugax as well as to those with hemispheric TIs.

Several substantial clinical trials (of unstable angina, patency of saphenous vein grafts, and TIA and minor stroke) have shown no difference in the effect of low (300–325 mg/day) versus high (900–1,300 mg/day) doses of aspirin, but a higher prevalence of side effects is associated with the high dose. For this reason, all recommendations at this time for aspirin are for 300–325 mg/day.

Dipyridamole and sulfinpyrazone have not been shown to confer additional benefit over aspirin alone in trials involving patients with TIA and minor stroke. Other nonsteroidal anti-inflammatory drugs or dipyridamole may have a place in the treatment of patients intolerant of aspirin. The combination of anticoagulant plus dipyridamole is used widely in patients with prosthetic heart valves.

Anticoagulation. No conclusive evidence on its effect in patients with amaurosis fugax is available. Trials testing warfarin in the prevention of stroke and TIA in patients with TIA involved too few patients to be conclusive or statistically significant.

Modifiable risk factors for stroke should be addressed, with particular attention to hypertension, hypercholesterolemia, and smoking.


**Therapeutic Failure**

*Medical failure.* If patients continue to have episodes of amaurosis fugax while taking aspirin, reevaluation of the possibility that the atherosclerotic process has worsened is important. If the disease has progressed to severe stenosis, surgical therapy may be indicated. If no change has occurred, aspirin may be continued or anticoagulation may be initiated.

*Surgical failure.* If the episodes continue after endarterectomy, other possibilities, such as inadequate surgical removal of plaque, restenosis, or a tandem lesion that may be serving as a source of microemboli to the eye, must be considered. Therapy must be individualized.

**Other Entities**

*Cardioembolism.* A cardiac cause requires the appropriate therapy, for example, anticoagulation for mural thrombus, aspirin for mitral valve prolapse, or cardiac surgery, as indicated after thorough cardiac assessment.

*Giant-cell arteritis.* If the sedimentation rate is elevated, patients with amaurosis fugax alone or accompanied by other symptoms suggesting giant-cell arteritis should be placed on high-dose corticosteroids to prevent visual loss secondary to anterior ischemic optic neuropathy or a central retinal artery occlusion. The patients then should be referred for consultation regarding further ocular evaluation and temporal artery biopsy. Further management should be based on the outcome of this evaluation.

*Migraine.* A few patients with migraine are stroke-prone. Generally, such patients have complicated migraine or uncomplicated migraine associated with risk factors for atherosclerosis (e.g., hypertension, hyperlipidemia, cigarette smoking) or with other risk factors for stroke (e.g., use of oral contraceptives, the puerperium). Patients <40 years of age who have amaurosis fugax and uncomplicated migraine appear to require no treatment for the amaurosis fugax, but oral contraceptives and cigarette smoking should be avoided. Patients who are >40 years of age or who have complicated migraine or other risk factors for stroke should be treated with 300–325 mg aspirin/day, and vasoconstrictor agents should be avoided.

*Idiopathic.* Patients <40 years of age who have typical amaurosis fugax without any obvious cause appear to be at very low risk for subsequent stroke or permanent visual loss; such patients require no treatment, but a history of drug abuse should be sought. Those >40 years of age are probably at higher risk and probably should be treated with 300–325 mg aspirin/day. In addition, efforts should be made to modify their risk factors for atherosclerosis. If their episodes of amaurosis fugax become frequent or prolonged, the diagnosis should be reconsidered, as should the need for further evaluation, particularly a search for a cardioembolic source.

**Conclusion**

These recommendations for treatment represent the current preferred practice by most members of the Amaurosis Fugax Study Group. Changes in preference may evolve with more and better data acquisition in the near future, particularly from current multicenter clinical trials. Until the results of current surgical trials are known, these recommendations are only an account of present-day belief and practice.

**References**


**KEY WORDS** • amaurosis fugax • cerebrovascular disorders • diagnosis
Current management of amaurosis fugax. The Amaurosis Fugax Study Group.

*Stroke.* 1990;21:201-208
doi: 10.1161/01.STR.21.2.201

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1990 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/21/2/201

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/